The antibodies attach to a part of the virus that doesn't appear to mutate, potentially allowing them to work on multiple ...

Australia’s newest authoritarian approach to controlling its political climate has been manufactured through the enactment of ...

High-profile Republican priorities are advancing after the Iowa Legislature's first "funnel" deadline on Friday, while others ...

Taiwan Semiconductor Manufacturing, Salesforce, Oracle, Exxon Mobil, ServiceNow, D-Wave Quantum, and Pfizer are the seven Manufacturing stocks to watch today, according to MarketBeat’s stock screener ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. The study was published in Cancer Discovery by ...

The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...

We’ve learned a lot about COVID-19 over the last five years, but big questions remain. Recent federal actions may hinder the disease’s management.

Currently, about 14.1 million Americans are experiencing long COVID symptoms, with nearly a quarter reporting significant activity limitations. Recent data also indicates that around 1.01 million ...

Beam Therapeutics announced positive initial data for BEAM-302 in the Phase I/II trial in Alpha-1 Antitrypsin Deficiency (AATD).

There is a word we should never have to utter during the next pandemic: “unprecedented”. That description was used so often, ...

Attorneys general from 17 states are preparing to take legal action against Dr. Anthony Fauci for his conduct during the ...

The National Institutes of Health - the world’s largest funder of vital biomedical research – is now facing deep cost-cutting ...